U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.83 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.11 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.46
    +2.70 (+2.55%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Silver

    19.77
    -0.51 (-2.50%)
     
  • EUR/USD

    1.0426
    -0.0057 (-0.54%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.59%)
     
  • USD/JPY

    135.1750
    -0.5530 (-0.41%)
     
  • BTC-USD

    19,444.35
    +525.94 (+2.78%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Recap: SI-BONE Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of SI-BONE (NASDAQ:SIBN) were flat in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 22.22% year over year to ($0.28), which beat the estimate of ($0.30).

Revenue of $22,144,000 rose by 11.78% year over year, which beat the estimate of $22,080,000.

Looking Ahead

SI-BONE hasn't issued any earnings guidance for the time being.

The upcoming fiscal year's revenue expected to be between $92,000,000 and $94,000,000.

How To Listen To The Conference Call

Date: Mar 08, 2021

View more earnings on SIBN

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/asejw3qq

Price Action

Company's 52-week high was at $33.45

Company's 52-week low was at $7.20

Price action over last quarter: Up 33.73%

Company Profile

SI-BONE Inc is a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.